Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on PYC Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Health Check: Just the news we ‘kneed’ as Paradigm aims to kick-start US osteo trial
News
Market Highlights: Gold, S&P 500 hit new highs as Netflix dazzles; and one global stock to watch
News
Closing Bell: Gold stocks lead ASX; Iris Metals surges on lithium battery conversion success
Health & Biotech
Health Check: The Winner Takes It All as US investors back advanced biotech plays
Health & Biotech
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
News
Market Highlights: US GDP boosts market confidence, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: PYC to start trials for rare eye disease; OncoSil device successful in tumour removal
Health & Biotech
Broker says PYC Therapeutics’ stock price could double, or even 10x if trials succeed
Health & Biotech
ASX Health Stocks: Psilocybin drug shows promise for fibromyalgia pain relief
Health & Biotech
ASX Health Stocks: PYC’s visionary drug shows promise; Spontan ED spray available under TGA program
Health & Biotech
ASX Health Stocks: Focus on retina-disease drug study draws eyes
Health & Biotech
Beyond Resources Part 2: ASX companies driving WA’s medical and life sciences sector
Health & Biotech
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Health & Biotech
